We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00688454
First Posted: June 3, 2008
Last Update Posted: April 9, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Condition
Hypercholesteremia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [ Time Frame: 3 visits within 10 weeks ]

Secondary Outcome Measures:
  • Tolerability of CRESTOR-therapy [ Time Frame: 3 visits within 10 weeks ]

Enrollment: 3392
Study Start Date: February 2007
Study Completion Date: January 2008
Groups/Cohorts
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients
Criteria

Inclusion Criteria:

  • Patients with hypercholesteremia who was never treated with statins before
  • Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland
ClinicalTrials.gov Identifier: NCT00688454     History of Changes
Other Study ID Numbers: NIS-CCH-CRE-2007/1
First Submitted: May 29, 2008
First Posted: June 3, 2008
Last Update Posted: April 9, 2009
Last Verified: April 2009

Keywords provided by AstraZeneca:
Hyperlipidemia
Rosuvastatin
Efficacy
tolerability
CRESTOR therapy

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors